Breast Cancer Research and Treatment

, Volume 149, Issue 1, pp 133–140 | Cite as

Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast

Clinical trial

Abstract

Primary squamous cell carcinoma of the breast (PSCCB) is a rare type of breast carcinoma, the clinical behavior of which has not been accurately characterized. The aim of this study was to evaluate its prevalence, characteristics, prognosis, and effective treatment modalities in patients attending our institution. The records of the Cancer Institute and Hospital of Tianjin Medical University from 1985 to 2013 were searched and 29 patients with PSCCB (0.086 % of all patients with breast cancer) identified. Their clinicopathological features, treatment methods used, and outcomes were analyzed. The median tumor size was 4.50 cm. Axillary lymph nodes metastases were present in 41.4 % of patients. The median overall survival was 39 months (range 7–144 months), with 34.5 % surviving at 5 years. The median relapse-free survival was 32 months (range 4–144 months), with 27.6 % relapse-free surviving at 5 years. According to univariate analysis, the time interval between onset of the first symptom and first presentation to a health professional (TI) (P = 0.017), use of adjuvant chemotherapy (P = 0.044), and T stage (P = 0.048, T1 vs. T2, T3, T4) were significant prognostic factors for overall survival. PSCCB is an extremely aggressive disease associated with large tumor size, rapid progression, frequent relapse, and a high death rate. Imaging findings are nonspecific and easily misinterpreted as benign. Cisplatin-based chemotherapy may be effective. Early diagnosis and treatment of this rare entity are critical to patient prognosis.

Keywords

Primary squamous cell carcinoma Breast cancer Characteristics Prognosis Therapeutic strategies 

Notes

Acknowledgments

This study was supported by the National Natural Science Foundation of China (Grant No. 81201725) and the Foundation of Tianjin Medical University Cancer Institute and Hospital (Grant No. 1310).

Conflict of interest

None of the authors has any competing interests to declare. The authors have no relevant financial interests to disclose.

References

  1. 1.
    Nayak A, Wu Y, Gilcrease MZ (2013) Primary squamous cell carcinoma of the breast: predictors of locoregional recurrence and overall survival. Am J Surg Pathol 37(6):867–873. doi: 10.1097/PAS.0b013e3182877569 PubMedCrossRefGoogle Scholar
  2. 2.
    Grenier J, Soria JC, Mathieu MC, Andre F, Abdelmoula S, Velasco V, Morat L, Besse B, Dunant A, Spielmann M, Delaloge S (2007) Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. Anticancer Res 27(1B):547–555PubMedGoogle Scholar
  3. 3.
    Siegelmann-Danieli N, Murphy TJ, Meschter SC, Stein ME, Prichard J (2005) Primary pure squamous cell carcinoma of the breast. Clin Breast Cancer 6(3):270–272. doi: 10.3816/CBC.2005.n.030 PubMedCrossRefGoogle Scholar
  4. 4.
    Hennessy BT, Krishnamurthy S, Giordano S, Buchholz TA, Kau SW, Duan Z, Valero V, Hortobagyi GN (2005) Squamous cell carcinoma of the breast. J Clin Oncol 23(31):7827–7835. doi: 10.1200/JCO.2004.00.9589 PubMedCrossRefGoogle Scholar
  5. 5.
    Wargotz ES, Norris HJ (1990) Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin. Cancer 65(2):272–276PubMedCrossRefGoogle Scholar
  6. 6.
    Brack K, Ramaekers PC, Tjalma WA (2003) Primary squamous cell carcinoma of the breast. Eur J Gynaecol Oncol 24(5):384–386PubMedGoogle Scholar
  7. 7.
    Honda M, Saji S, Horiguchi S, Suzuki E, Aruga T, Horiguchi K, Kitagawa D, Sekine S, Funata N, Toi M, Kuroi K (2011) Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast. Surg Today 41(3):328–332. doi: 10.1007/s00595-009-4276-2 PubMedCrossRefGoogle Scholar
  8. 8.
    Pandit S, Singal R, Goyal S, Mahajan NC, Aneja R, Kaushik N, Jain S, Singal S (2013) A rare clinicopathological presentation of the breast carcinoma; implications and outcome. Int J Prev Med 4(7):845–848PubMedCentralPubMedGoogle Scholar
  9. 9.
    Troell A (1908) Zwei Falle von Palttenepithelcarcinom. Nord Med Ark 1:1–11Google Scholar
  10. 10.
    Rosen PP (2009) Breast pathology. In: Rosen PP (ed) Rosen’s breast pathology, 3rd edn. Lippincott Williams and Wilkins, PhiladelphiaGoogle Scholar
  11. 11.
    Aparicio I, Martinez A, Hernandez G, Hardisson D, De Santiago J (2008) Squamous cell carcinoma of the breast. Eur J Obstet Gynecol Reprod Biol 137(2):222–226. doi: 10.1016/j.ejogrb.2007.03.021 PubMedCrossRefGoogle Scholar
  12. 12.
    Gunhan-Bilgen I, Memis A, Ustun EE, Zekioglu O, Ozdemir N (2002) Metaplastic carcinoma of the breast: clinical, mammographic, and sonographic findings with histopathologic correlation. AJR Am J Roentgenol 178(6):1421–1425. doi: 10.2214/ajr.178.6.1781421 PubMedCrossRefGoogle Scholar
  13. 13.
    Choi BB, Shu KS (2012) Metaplastic carcinoma of the breast: multimodality imaging and histopathologic assessment. Acta Radiol 53(1):5–11. doi: 10.1258/ar.2011.110341 PubMedCrossRefGoogle Scholar
  14. 14.
    Tashjian J, Kuni CC, Bohn LE (1989) Primary squamous cell carcinoma of the breast: mammographic findings. Can Assoc Radiol J 40(4):228–229PubMedGoogle Scholar
  15. 15.
    Flikweert ER, Hofstee M, Liem MS (2008) Squamous cell carcinoma of the breast: a case report. World J Surg Oncol 6:135. doi: 10.1186/1477-7819-6-135 PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Song Y, Liu X, Zhang G, Song H, Ren Y, He X, Wang Y, Zhang J, Zhang Y, Sun S, Liang X, Sun Q, Pang D (2013) Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators. World J Surg Oncol 11:129. doi: 10.1186/1477-7819-11-129 PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Tsung SH (2012) Primary pure squamous cell carcinoma of the breast might be sensitive to Cisplatin-based chemotherapy. Case Rep Oncol 5(3):561–565. doi: 10.1159/000343745 PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Hiramatsu K, Kato K, Hirata A, Matsuba H, Hara T, Ito T, Miyata T, Akagawa T, Kutsuna Y, Machiki Y, Fujioka S (2007) A resected case of squamous cell carcinoma of the breast successfully treated by FU plus cisplatin (CDDP) adjuvant therapy against recurrent metastases. Gan To Kagaku Ryoho 34(3):443–446PubMedGoogle Scholar
  19. 19.
    Dejager D, Redlich PN, Dayer AM, Davis HL, Komorowski RA (1995) Primary squamous cell carcinoma of the breast: sensitivity to cisplatinum-based chemotherapy. J Surg Oncol 59(3):199–203PubMedCrossRefGoogle Scholar
  20. 20.
    Kashiwagi S, Okuno T, Ishihara S, Ishii M, Asano Y, Watanabe M, Morisaki T, Aomatsu N, Noda S, Kawajiri H, Nakano T, Kawakami N, Mitsukawa Y, Takashima T, Onoda N, Ishikawa T, Hirakawa K (2013) Effectiveness of eribulin chemotherapy for squamous cell carcinoma of the breast. Gan To Kagaku Ryoho 40(12):2369–2371PubMedGoogle Scholar
  21. 21.
    Stevenson JT, Graham DJ, Khiyami A, Mansour EG (1996) Squamous cell carcinoma of the breast: a clinical approach. Ann Surg Oncol 3(4):367–374PubMedCrossRefGoogle Scholar
  22. 22.
    Senga O, Hikita H, Kinoshita T, Hara K, Miyakawa M, Nishimura H, Tsuchiya S (1993) Primary squamous cell carcinoma of the breast in a pregnant woman: report of a case. Surg Today 23(6):541–545PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Breast Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerKey Laboratory of Cancer Prevention and TherapyTianjinChina
  2. 2.Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical UniversityMinistry of EducationTianjinChina
  3. 3.Department of Thyroid and Neck Tumors, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for CancerKey Laboratory of Cancer Prevention and TherapyTianjinChina

Personalised recommendations